Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: Effect on Pain Control
NCT ID: NCT02858622
Last Updated: 2019-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
44 participants
INTERVENTIONAL
2016-12-31
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ultrasound Guided Transversus Abdominis Plane Block in Pediatric Surgery
NCT02723487
TAP vs Caudal Block Using Dexmedetomidine/ Bupivacaine for Post Operative Analgesia
NCT03482947
Ultrasound Guided Subcostal Transversus Abdominis Plane Block Versus Quadratus Lumborum Block for Pediatrics Undergoing Pyeloplasty.
NCT04269460
Fascia Transversalis Versus Transversus Abdominis Plane Block for Children Undergoing Inguinal Hernia Surgery
NCT06326944
Transversus Abdominis Plane Versus Caudal Block for Pediatrics
NCT02398123
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dual TAB group
22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg
bupivacaine
bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
Pethidine
pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
perfalgan
intravenous paracetamol
fentanyl
control group
22 patients who will not receive dual TAB block
Pethidine
pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
perfalgan
intravenous paracetamol
fentanyl
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bupivacaine
bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
Pethidine
pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
perfalgan
intravenous paracetamol
fentanyl
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* end stage renal disease
* no known allergy to bupivacaine
* both sexes
Exclusion Criteria
3 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherif Mohamed Abd el moneim Soaida, MD
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sherif M Soaida, M.D.
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of medicine, Cairo University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMS2016-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.